Drugs / Alloreactive NK cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase not applicable2 trials | ||||||
| — | NCT06885476 | Jan 2021 → Dec 2025 overdue | acute myeloid leukemia | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Recruiting | No outcome recorded |
| — | NCT03955848 | May 2018 → May 2019 | acute myeloid leukemia | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT05304754 Comparator | Nov 2020 → Jun 2026 overdue | — | Instituto de Investigación Hospital Universitario La Paz | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | alloreactive NK cells | “Alloreactive NK cells” NCT03955848 ↗ |
| Modality | Cell therapy | “Alloreactive NK cell infusion” NCT03955848 ↗ |
| Route | Intravenous | “infused intravenously” NCT03955848 ↗ |